News & Articles tyrosine kinase inhibitor Ariad's Iclusig in GIST Phase II Study The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor therapy. June 18, 2013 - Zacks via Yahoo! Finance